Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07244770
Active, not recruiting Observational

The Effects of Some Antihyperglycemic Drugs on Cognitive Function and Risk of Depression of Diabetic Patients

NCT07244770 · tracked via the Priya Life Science Egypt tracker
Sponsor
Beni-Suef University
Phase
Observational
Started
2025-01-01
Last updated
2026-07-24

Condition(s) studied

MCI

Investigational drug(s) / intervention(s)

SGLT2 Is+METFORMIN →DPP4 Is+metformin →Control group

SGLT2 Is+METFORMIN: Patients administering SGLT2 Is+metformin added to their treatment for at least the past 12 months

DPP4 Is+metformin: Patients administering DPP4 I+ metformin added to their treatment for at least the past 12 months

Control group: patients administered their standard of care without any changes for the past 6 months

Study summary

The study aims to investigate the effects of DPP-4 Is+ metformin versus SGLT2 Is + metformin on the risk of cognitive decline and depression in patients with T2DM.

Eligibility

Sex
ALL
Min age
55 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: \- The study participants should meet the following inclusion criteria: 1. T2DM adult subjects (\>55 years old) will be eligible to participate. 2. Patients should be taking SGLT2Is+metformin or DDP4Is + metformin for at least 1 year to be eligible. Exclusion Criteria: 1- Those with type1 diabetes or ketoacidosis, insulin therapy, end organ failure as chronic renal failure, liver, and heart failure, previous history of pancreatitis, history of Alzheimer's disease or any brain insult, and finally pregnant or lactating females will be excluded from the study.

Primary outcome measure(s)

  • MCI — Day 1
    Changes in Montreal Cognitive Assessment (MoCA) score
  • Depression — Day 1
    Changes in Patient Health Questionnaire-9 (PHQ-9) score

Trial sites (1)

FacilityCityRegionStatus
Beni Suef Hospital Banī Suwayf Egypt

More Beni-Suef University trials in Egypt

Renal SWE as a Predictor After Pediatric Pyeloplasty for UPJO Recruiting
Efficacy of Alpha Lipoic Acid Combined With Myo-Inositol in Non-Diabetic PCOS Patients Recruiting
Comparison of Supra-abdominal ex Versus Infra-abdominal With Laser on Median Sternotomy Starting soon
Efficacy of Pulsed Electromagnetic Field Therapy on Women With Endometriosis Recruiting
Assessment of Emergency Spacers Versus Traditional Spacers for Delivery of Aerosolized Drugs Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07244770 on ClinicalTrials.gov ↗ ← All trials in Egypt